Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Psyence Group Inc. C.PSYG

Alternate Symbol(s):  PSYGF

Psyence Group Inc is a science-led psychedelic platform led by experts in neurology, neuroscience, and drug development. The company builds and operates federally licensed commercial psilocybin cultivation and production facilities.


Recent & Breaking News (CSE:PSYG)

Psyence and Eden Labs Announce Extraction and Product Development Collaboration

GlobeNewswire 7 days ago

Psyence (CSE:PSYG) exports pharma-grade psilocybin extract to the U.K.

Jon Brown 11 days ago

Psyence Group Completes Export of Pharma Grade Psilocybin Extract to UK

GlobeNewswire 11 days ago

Psyence (CSE:PSYG) announces business combination and signs LOI with Australian CRO iNGENū

John Ballem  January 16, 2023

Psyence Announces Business Combination between Wholly Owned Subsidiary Psyence Biomed Corp. and Nasdaq listed Newcourt Acquisition Corp

GlobeNewswire January 9, 2023

Psyence Signs Letter of Intent with Australian CRO iNGENū

GlobeNewswire January 8, 2023

Psyence (CSE:PSYG) and Filament Health (NEO:FH) announce licensing agreement of psilocybin capsules for palliative care

John Ballem  December 19, 2022

Psyence and Filament Health Announce Worldwide Licensing Agreement of Psilocybin Capsule for Palliative Care

GlobeNewswire December 15, 2022

Psyence Group (CSE:PSYG) closes second tranche of $3M private placement

Azuka Onwuka December 14, 2022

Psyence Group Announces Closing of Second Tranche of Private Placement and Appointment of Strategic Advisor

GlobeNewswire December 14, 2022

Psyence Group (CSE:PSYG) signs distribution agreement with This Works Products Ltd.

Shoran Devi November 29, 2022

GOODMIND(TM) Available for Sale in the United Kingdom and Europe - Exclusive Distribution Agreement Concluded With This Works

GlobeNewswire November 29, 2022

Psyence Group Announces Strategic Private Placement

GlobeNewswire November 10, 2022

Psyence Group (CSE:PSYG) exports psilocybin mushrooms to Canada and Portugal

John Ballem  October 3, 2022

Psyence Group Completes Export of Psilocybin Mushrooms to Portugal

GlobeNewswire September 29, 2022

Psyence Group Completes Export of Psilocybin Mushrooms to Canada

GlobeNewswire September 22, 2022

Psyence Group (CSE:PSYG) receives Phase IIa clinical trial approval from the UK MHRA

Jon Brown September 20, 2022

Psyence Group Receives Phase IIa Clinical Trial Approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA)

GlobeNewswire September 19, 2022

Psyence Group (CSE:PSYG) closes first tranche of amended private placement

John Ballem  September 7, 2022

Psyence Group Announces Amendment and Closing of Previously Announced Private Placement

GlobeNewswire September 7, 2022